| Issue |
Med Sci (Paris)
Volume 42, Number 2, Février 2026
Chroniques génomiques
|
|
|---|---|---|
| Page(s) | 209 - 211 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/2026021 | |
| Published online | 24 February 2026 | |
Un château de cartes ?
House of cards?
Biologiste, généticien, Président d’Aprogène (association pour la promotion de la génomique), Marseille, France
*
This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Enthusiasm for multi cancer early detection tests remains high, with many companies involved and, notably, significant sales of a non-FDA-approved, non-reimbursed test. This contrasts with the still incomplete clinical validation of these tests. Such unjustified hype is not unheard of in the biotech world…
© 2026 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l’utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.